Villere ST Denis J & Co. LLC Purchases 63,000 Shares of CollPlant Biotechnologies Ltd. Sponsored ADR $CLGN

Villere ST Denis J & Co. LLC raised its position in shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 13.0% in the second quarter, HoldingsChannel reports. The firm owned 546,867 shares of the company’s stock after buying an additional 63,000 shares during the quarter. Villere ST Denis J & Co. LLC’s holdings in CollPlant Biotechnologies were worth $744,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, AMH Equity Ltd increased its position in CollPlant Biotechnologies by 7.3% in the first quarter. AMH Equity Ltd now owns 125,000 shares of the company’s stock worth $322,000 after buying an additional 8,500 shares in the last quarter. 21.69% of the stock is owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Trading Down 6.0%

NASDAQ:CLGN opened at $2.20 on Friday. CollPlant Biotechnologies Ltd. Sponsored ADR has a 12-month low of $1.31 and a 12-month high of $4.99. The stock has a 50-day moving average price of $2.60 and a 200 day moving average price of $2.24. The stock has a market capitalization of $27.98 million, a P/E ratio of -1.95 and a beta of 1.57.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its earnings results on Wednesday, August 20th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.57). CollPlant Biotechnologies had a negative return on equity of 94.08% and a negative net margin of 541.34%.The business had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $8.91 million. On average, research analysts predict that CollPlant Biotechnologies Ltd. Sponsored ADR will post -1.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Wednesday. D. Boral Capital restated a “buy” rating and issued a $12.00 price target on shares of CollPlant Biotechnologies in a research report on Tuesday, September 16th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a research report on Thursday, August 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.